Compugen Ltd.
CGENAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 21, 2026 | Leerink Partners | $5.00(+85%) | $2.71 | TheFly | |
| Jan 7, 2026 | H.C. Wainwright | $4.00(+158%) | $1.55 | TheFly | |
| May 21, 2024 | Truist Financial | Asthika Goonewardene | $4.00(+130%) | $1.74 | TheFly |
| May 20, 2024 | Stifel Nicolaus | Stephen Willey | $4.00(+130%) | $1.74 | StreetInsider |
| May 20, 2024 | Truist Financial | Asthika Goonewardene | $5.00(+187%) | $1.74 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Oct 12, 2026 |
| Leerink Partners | maintain | Outperform | May 21, 2026 |
| Truist Securities | maintain | Buy | May 21, 2024 |
| Truist Securities | maintain | Buy | Mar 8, 2024 |
| Stifel | maintain | Buy | Dec 19, 2023 |
| Truist Securities | maintain | Buy | Aug 23, 2023 |
| EF Hutton | maintain | Buy | Aug 7, 2023 |
| EF Hutton | maintain | Buy | Jun 6, 2023 |
| EF Hutton | maintain | Buy | May 26, 2023 |
| EF Hutton | maintain | Buy | May 24, 2023 |
| Oppenheimer | maintain | Outperform | May 16, 2023 |
| Oppenheimer | maintain | Outperform | Feb 28, 2023 |
| Jefferies | downgrade | Hold →Underperform | Feb 8, 2023 |
| EF Hutton | maintain | Buy | Jan 5, 2023 |
| Oppenheimer | maintain | Outperform | Nov 15, 2022 |
| Truist Securities | maintain | Buy | Aug 23, 2022 |
| JMP Securities | maintain | Market Outperform | Aug 8, 2022 |
| Oppenheimer | maintain | Outperform | Aug 8, 2022 |
| Jefferies | downgrade | Buy →Hold | Aug 5, 2022 |
| Oppenheimer | maintain | Outperform | Feb 25, 2022 |
| SVB Leerink | maintain | Outperform | Feb 25, 2022 |
| SVB Leerink | maintain | Outperform | Apr 6, 2021 |
| SVB Leerink | maintain | Outperform | Aug 19, 2020 |
| Stifel | maintain | Buy | May 13, 2020 |
| SVB Leerink | maintain | Outperform | May 7, 2020 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 3, 2026 | $-0.07 | $-0.08 | $2.6M | $1.3M |
| May 18, 2026 | $-0.08 | $-0.07 | $2.2M | $1.6M |
| Mar 2, 2026 | $0.60 | $-0.07 | $67.3M | $2.2M |
| Nov 10, 2025 | $-0.07 | $-0.09 | $1.9M | $1.2M |
| Aug 6, 2025 | $-0.08 | $-0.07 | $1.3M | $4.0M |
| May 19, 2025 | $-0.08 | $-0.06 | $2.3M | $3.2M |
| Mar 4, 2025 | $-0.07 | $0.07 | $1.5M | $13.0M |
| Nov 12, 2024 | $0.01 | $0.06 | $17.1M | $1.3M |
News
HOLON, Israel, Nov. 3, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in the following upcoming investor conferences in November 2026: Stifel 2026 Healthcare Conference Date: Tuesday, November 10, 2026Location: New York, NYFormat: Fireside chat and 1x1 meetingsFireside chat time: 11:20 am ET 2026 Jefferies Global Healthcare …
Compugen (NASDAQ: CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event. President and Chief Executive Officer Eran Ophir said COM701, a wholly owned anti-PVRIG antibody, is the company's most advanced internal program.
HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C.
Compugen NASDAQ: CGEN outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event.
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
Compugen (NASDAQ: CGEN - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings and Valuation This table compares Compugen and
HOLON, Israel, Sept. 22, 2026 /PRNewswire/ -- Compugen Ltd.
HOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd.
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.